ATE229031T1 - 6,7-oxygenierte steroide und deren verwendung - Google Patents

6,7-oxygenierte steroide und deren verwendung

Info

Publication number
ATE229031T1
ATE229031T1 AT97929071T AT97929071T ATE229031T1 AT E229031 T1 ATE229031 T1 AT E229031T1 AT 97929071 T AT97929071 T AT 97929071T AT 97929071 T AT97929071 T AT 97929071T AT E229031 T1 ATE229031 T1 AT E229031T1
Authority
AT
Austria
Prior art keywords
oxygen substitution
steroids
disclosed
steroid
functionality
Prior art date
Application number
AT97929071T
Other languages
English (en)
Inventor
David L Burgoyne
Yaping Shen
John M Langlands
Christine Rogers
Joseph H-L Chau
Edward Piers
Hassan Salari
Original Assignee
Inflazyme Pharm Ltd
Univ British Columbia
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazyme Pharm Ltd, Univ British Columbia, Univ Alberta filed Critical Inflazyme Pharm Ltd
Application granted granted Critical
Publication of ATE229031T1 publication Critical patent/ATE229031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT97929071T 1996-07-11 1997-07-11 6,7-oxygenierte steroide und deren verwendung ATE229031T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2345096P 1996-07-11 1996-07-11
US67964296A 1996-07-12 1996-07-12
PCT/CA1997/000490 WO1998002450A2 (en) 1996-07-11 1997-07-11 6,7-oxygenated steroids and uses related thereto

Publications (1)

Publication Number Publication Date
ATE229031T1 true ATE229031T1 (de) 2002-12-15

Family

ID=26697171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929071T ATE229031T1 (de) 1996-07-11 1997-07-11 6,7-oxygenierte steroide und deren verwendung

Country Status (13)

Country Link
US (5) US6046185A (de)
EP (1) EP0917534B1 (de)
JP (1) JP2001503732A (de)
KR (1) KR100533436B1 (de)
AT (1) ATE229031T1 (de)
AU (1) AU722815B2 (de)
BR (1) BR9710353A (de)
CA (1) CA2259981C (de)
DE (1) DE69717633T2 (de)
ES (1) ES2187788T3 (de)
NZ (1) NZ333731A (de)
RU (1) RU2196143C2 (de)
WO (1) WO1998002450A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
ATE258444T1 (de) * 1998-03-13 2004-02-15 Univ British Columbia Therapeutische chemokine rezeptor antagonisten
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
OA12255A (en) * 2000-04-28 2006-05-11 Inflazyme Pharm Ltd 3-Nitrogen-6,7-dioxygen steroids and uses related thereto.
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
PL367097A1 (en) * 2001-05-21 2005-02-21 Alcon, Inc. Method of treating dry eye disorders
BR0209965A (pt) 2001-05-21 2004-04-06 Alcon Inc Uso de inibidores de nf-kappab para tratar distúrbios do olho seco
KR20040017219A (ko) * 2001-05-22 2004-02-26 인플라자임 파마슈티칼즈 리미티드 스테로이드 화학의 개선방법
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
GB0217930D0 (en) * 2002-08-02 2002-09-11 Glycologic Ltd A chemical carrier
EP1615944A4 (de) * 2003-04-01 2010-08-11 Harbor Biosciences Inc Antiandrogene mit marginaler agonistenwirkung und anwendungsverfahren
EP3156387B1 (de) 2003-04-15 2018-07-25 Aquinox Pharmaceuticals (Canada) Inc. Methode zur herstellung von indenderivaten
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
JP2008531584A (ja) * 2005-02-25 2008-08-14 エフィカス・インコーポレイテッド マタタビ属を含む組成物およびそれを用いる方法
US8871779B2 (en) * 2006-03-02 2014-10-28 Mallinckrodt Llc Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN102617685B (zh) * 2012-03-08 2014-01-22 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
HK1220173A1 (zh) 2013-03-14 2017-04-28 Aquinox Pharmaceuticals (Canada) Inc. Ship1调节剂和与其相关的方法
CA2902768A1 (en) 2013-03-14 2014-10-02 Aquinox Pharmaceuticals (Canada) Inc. Ship1 modulators and methods related thereto
CN104072564B (zh) * 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
JP2018518494A (ja) 2015-06-26 2018-07-12 アクイノックス ファーマシューティカルズ （カナダ） インコーポレイテッド （１Ｓ，３Ｓ，４Ｒ）−４−（（３ａＳ，４Ｒ，５Ｓ，７ａＳ）−４−（アミノメチル）−７ａ−メチル−１−メチレンオクタヒドロ−１Ｈ−インデン−５−イル）−３−（ヒドロキシメチル）−４−メチルシクロヘキサノールの酢酸塩の結晶固体形態
US10053415B2 (en) 2016-01-20 2018-08-21 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
JP2019508424A (ja) 2016-03-02 2019-03-28 パセオン オーストリア ゲーエムベーハー ウント ツェーオー カーゲー １７（２０）−エン ｂ−セコステロイドの生産のためのプロセスと中間体
JP6892278B2 (ja) * 2017-02-10 2021-06-23 あすか製薬株式会社 １５−オキソステロイド化合物及びその製造方法
WO2019195777A1 (en) 2018-04-06 2019-10-10 Aquinox Pharmaceuticals (Canada) Inc. Indene derivatives useful in treating pain and inflammation
AU2019247496A1 (en) 2018-04-06 2020-10-22 Taro Pharmaceuticals Inc. Indene derivatives useful in treating pain and inflammation
EP4292655A2 (de) 2018-04-06 2023-12-20 Taro Pharmaceuticals Inc. Zur behandlung von schmerzen und entzündungen nützliche hexadecahydro-1h-cyclopenta[a]phenanthren-derivate
WO2023213151A1 (zh) * 2022-05-06 2023-11-09 奥锐特药业股份有限公司 一种醋酸阿比特龙及其中间体的制备方法
CN116574151A (zh) * 2023-03-13 2023-08-11 奥锐特药业股份有限公司 一种醋酸阿比特龙及其中间体的制备方法
CN116178475B (zh) * 2023-03-13 2025-07-29 奥锐特药业股份有限公司 一种醋酸阿比特龙及其中间体的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026320A (en) * 1958-11-28 1962-03-20 Syntex Sa Derivatives of cortisone and hydrocortisone
JPS4122178Y1 (de) * 1964-12-16 1966-11-04
US3681410A (en) * 1970-08-07 1972-08-01 Syntex Corp Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof
BE792321A (fr) * 1971-12-08 1973-06-05 Roussel Uclaf Nouveaux 18,19-dinor 13,beta-alcoyl pregna 4,9,11-trienes et procede depreparation
ES427522A1 (es) * 1973-06-25 1976-12-16 Scherico Ltd Un procedimiento para la preparacion de un 3-ceto-6-arido-4.6-bis-deshidroesteroide.
CH606090A5 (de) * 1974-07-30 1978-10-13 Ciba Geigy Ag
GB1490852A (en) * 1974-09-12 1977-11-02 Leo Pharm Prod Ltd Fusidic acid derivatives
US5002961A (en) * 1987-10-19 1991-03-26 Merrell Dow Pharmaceuticals Method for reducing injury with imidazol-2-thionecarboxamides
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
DK603988D0 (da) * 1988-10-28 1988-10-28 Klaus Bendtzen Farmaceutisk praeparat
DE4005516A1 (de) * 1989-02-24 1990-08-30 Henkel Corp Verfahren zur umwandlung (alpha)-acetyl-substituierter lactone in (alpha)-alkyliden-substituierte lactone
US5079239A (en) * 1990-02-16 1992-01-07 Harbor Branch Oceanographic Institution, Inc. Sterol disulfates and methods of use
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
CA2086221C (en) * 1992-12-23 2003-07-15 Raymond J. Andersen Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent
US5506221A (en) * 1992-12-24 1996-04-09 University Of British Columbia Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agents
US5763435A (en) * 1995-11-21 1998-06-09 Children's Hospital Medical Center Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders

Also Published As

Publication number Publication date
US6706701B1 (en) 2004-03-16
KR100533436B1 (ko) 2006-01-09
US20060211857A1 (en) 2006-09-21
US20040157814A1 (en) 2004-08-12
KR20000023661A (ko) 2000-04-25
CA2259981A1 (en) 1998-01-22
BR9710353A (pt) 2000-01-11
DE69717633T2 (de) 2003-10-02
RU2196143C2 (ru) 2003-01-10
WO1998002450A2 (en) 1998-01-22
US6046185A (en) 2000-04-04
US20040162425A1 (en) 2004-08-19
AU722815B2 (en) 2000-08-10
EP0917534B1 (de) 2002-12-04
JP2001503732A (ja) 2001-03-21
US6949533B2 (en) 2005-09-27
EP0917534A2 (de) 1999-05-26
DE69717633D1 (de) 2003-01-16
US7067682B2 (en) 2006-06-27
CA2259981C (en) 2008-06-10
ES2187788T3 (es) 2003-06-16
NZ333731A (en) 2000-09-29
AU3332397A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
DE69717633D1 (de) 6,7-oxygenierte steroide und deren verwendung
MX9303826A (es) Glicosidos esteroidales como agentes hipocolesterolemicos y agentes antiaterosclerosis.
ES2155874T3 (es) Composiciones cosmeticas que contienen acido betulinico.
BR0014189A (pt) Derivados de ácidos substituìdos úteis como agentes antidiabéticos e antiobesidade e método
TR199701544T1 (xx) Yeni dolastatin t�revleri,bunlar�n haz�rlanmas� ve kullan�lmas�.
ATE206035T1 (de) Haferextrakte enthaltende sonnenschutzmittel
ATE241337T1 (de) Hautpflegemittel für gealterte haut
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
BR9911040A (pt) 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos
DE69334183D1 (de) Von cyclodextrinen stabilisierter radiopharmazeutischer reagenzsatz
DE69523622D1 (de) Diastereomerenreine 3-oxo und 3-thioxo-4-aza-androstanderivate und ihre verwendung als antiandrogene
DE60123242D1 (de) Verwendung von (1-ethoxyethoxy)cyclododecan in einer parfümzusammensetzung als fixiermittel und/oder parfümverstärker
AU562646B2 (en) 1-alkyl-androsta-1, 4-diene-3, 17-diones
PT1135403E (pt) 17beta-acil-19alfa-propinil-11beta-arilesteroides e os seus derivados que tem propriedades hormonais agonistas ou antagonistas
DE69939171D1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
FI890302L (fi) Parannus androsta-1,4-dieeni-3,17-dionin 6-metyleenijohdannaisten synteesissä
ATE451107T1 (de) 3-o-sulfamatsteroidderivate als hemmer von estronsulfatase
BR9610930A (pt) Composição depilatória incluindo uma quantidade funcional de um agente tixoitrópico, e, uso da quantidade funcional de um agente tixotrópico.
NO20023276D0 (no) Fremgangsmåte til å fremstille betulinsyre
DE69311742D1 (de) Neue steroide
DE69628743D1 (de) Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen
ATE145213T1 (de) Kardioaktive steroide
DE69632407D1 (de) Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
FI853560L (fi) Foerfarande foer framstaellning av pregnanderivat.
PT1196428E (pt) Esteroides substituidos com 11 beta-aril-17, 17-espirotiolano

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0917534

Country of ref document: EP

REN Ceased due to non-payment of the annual fee